ISO 9001:2015 Certified
Live Customer Support
4.5/5 on Trustpilot
100% Quality Guarantee

Vunakizumab Biosimilar - Anti-IL-17A Antibody - Low endotoxin, Azide free (A323840)

Recombinant human monoclonal antibody to IL-17A for ELISA, FACS, Functional Assay and In Vivo.

Shipping Information

$40
Dispatched from St. Louis, MO.
Lead Time: 12-18 business days.
Name
Vunakizumab Biosimilar - Anti-IL-17A Antibody - Low endotoxin, Azide free
Description
Recombinant human monoclonal antibody to IL-17A.
Applications
ELISA, FACS, Functional Assay, In Vivo
Reactivity
Human, Rat, Mouse, Cynomolgus Macaque
Host
Human
Clonality
Monoclonal
Isotype
IgG1
Light Chains
kappa
Conjugate

Unconjugated

Purification
Protein A affinity chromatography.
Concentration
Reconstitution dependent.
Molecular Weight
This antibody has a predicted MW of 146.38 kDa.
Purity
> 95% (by SDS-PAGE and SEC-HPLC).
Product Form
Lyophilized
Reconstitution
Reconstitute with 100µl of sterile double-distilled water to bring antibody to 1mg/ml concentration. Gently shake to solubilize completely. Do not vortex!
Formulation
Lyophilized from 25mM Histadine, pH 6.2, with 8% Sucrose and 0.01% Tween80.
Storage
Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at -80°C. Product is stable for one year. Avoid freeze/thaw cycles.
Synonyms
CTLA-8, CTLA8, Cytotoxic T-lymphocyte-associated antigen 8, IL-17, IL17, IL17A, Interleukin-17A
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.
Publishing research using Vunakizumab Biosimilar - Anti-IL-17A Antibody - Low endotoxin, Azide free (A323840)? Please let us know so that we can list the citation on this page.

Alternative products to Vunakizumab Biosimilar - Anti-IL-17A Antibody - Low endotoxin, Azide free (A323840)

Proteins predicted to interact with IL-17A

Predicted protein interactions based upon String database. Revelancy score correlates with probability of interaction.
99.9% Relevancy Score
99.9% Relevancy Score
99.4% Relevancy Score
98.4% Relevancy Score
98% Relevancy Score
98% Relevancy Score
97.8% Relevancy Score
97.6% Relevancy Score
97.2% Relevancy Score